Loading
Mahkam Zanganeh received $1.0M in total compensation as Co-Chief Executive Officer, President and Director of Summit Therapeutics Inc. in FY2025. The largest component was $617K in base salary. That’s down 12% from FY2024. Source: SEC DEF 14A.
In fiscal year 2025, Mahkam Zanganeh, Co-Chief Executive Officer, President and Director of Summit Therapeutics Inc. (SMMT), received total compensation of $1.0 million.
Mahkam Zanganeh's compensation breakdown includes: base salary of $617K, bonus of $388K, and other compensation of $21K.
Compared to fiscal year 2024, Mahkam Zanganeh's total compensation increased 547% from $159K to $1.0 million.
Summit Therapeutics Inc.'s top 3 named executive officers received combined total compensation of $2.2 million in fiscal year 2025.
The named executive officers disclosed in Summit Therapeutics Inc.'s 2025 proxy statement are:Robert W. Duggan (Co-Chief Executive Officer and Chairman) with total compensation of $172K, Mahkam Zanganeh (Co-Chief Executive Officer, President and Director) with total compensation of $1.0 million, and Manmeet Soni (Chief Operating Officer, Chief Financial Officer and Director) with total compensation of $1.0 million.
Source Filing
Executive Record
Mahkam Zanganeh
Co-Chief Executive Officer, President and Director
Reported Pay
$1.0M
Summary compensation table total · FY2025
Findings
Reviewing FY2025 compensation of $1.0M against -2% shareholder return and the latest filing-backed pay disclosures.
Reported pay changed -12%; spread versus stock performance is pending computation.
Evidence is sourced from the latest executive compensation filing and return series for SMMT.
Team view
3 executives
Co-Chief Executive Officer and Chairman
Total PayFY2025
$172K
Co-Chief Executive Officer, President and Director
Total PayFY2025
$1.0M
Chief Operating Officer, Chief Financial Officer and Director
Total PayFY2025
$1.0M
Ask a question about this filing
01FY2025 total compensation breakdown
$1.0M total compensation
Mahkam Zanganeh earned $1.0M in FY2025— here's how that breaks down.
$616.5K
60% of total
$388.4K
38% of total
$21.0K
2% of total
Activity timeline · FY2025
Recent events from filings
Jan 2, 2025
Robert W. Duggan Equity award (Grant FV $172,376, Exercise $18.35)
A pay-performance summary will appear here once the verdict loads above.
02Pay changes vs. stock performance
1 year of data
Peer context
Dashed line marks the large-cap median compensation benchmark for companies around $13.1B market cap, based on 338 peers in this size band.
03Recent insider trades by officers and directors
~32 trades
04FY2026 board composition and compensation
We're loading the latest director compensation and board makeup.
05Take action on executive compensation
Shareholder activism tools
Start or join campaigns to engage with SMMT's board on executive compensation, governance, and shareholder proposals.
Activism Beta — Sign in to start or join campaigns
06For analysts and deep research
Historical compensation data from latest proxy filing
| Year | Executive | Salary | Bonus & Incentive | Stock Awards | Option Awards | Other Adj. | Total |
|---|---|---|---|---|---|---|---|
| 2025 | $0.62M | $0.39M | $0.00M | $0.00M | $0.02M | $1.03M | |
| 2024 | $0.60M | $0.54M | $0.00M | $0.00M | $0.02M | $1.16M | |
| 2023 | $0.60M | $0.00M | $0.00M | $19.9M | $0.06M | $20.6M | |
| 2022 | $0.45M | $0.45M | $0.00M | $0.31M | $0.03M | $1.24M | |
| 2021 | $0.45M | $0.18M | $0.00M | $8.99M | $0.02M | $9.64M |
Salary = base cash pay. Bonus & Incentive combines annual bonus and non-equity plans. Equity amounts are grant-date fair values. Other Adj. captures pension changes, perquisites, and any reconciliation items so the total matches the reported figure.
Get one email when new executive compensation data is filed and processed.
Summit Therapeutics Inc. (SMMT) — Key Facts
Last updated May 3, 2026 · DEF 14A filed Apr 17, 2026
| CEO | Mahkam Zanganeh, Co-Chief Executive Officer, President and Director |
|---|---|
| Fiscal year | FY2025 |
| Total compensation | $1.0M |
| Base salary | $617K |
| Other compensation | $21K |
| Year-over-year change | -12% |
| Source | DEF 14A, 2026-04-17 |
Mahkam Zanganeh, the Co-Chief Executive Officer, President and Director of Summit Therapeutics Inc., received total compensation of $1.0 million in fiscal year 2025. This includes base salary of $616,500.
Mahkam Zanganeh's base salary at Summit Therapeutics Inc. is $616,500 per year as of fiscal year 2025. However, total compensation including stock awards, bonuses, and other benefits is $1.0 million.
Summit Therapeutics Inc.'s CEO, Mahkam Zanganeh, earned $1.0 million in total compensation for fiscal year 2025.